

1 Gut microbiota analyses of Saudi populations for type 2 diabetes-related phenotypes
2 reveals significant association
3

4 Fahd A Al-Muhanna¹, Alexa K. Dodwell², Abdulmohsen H Al Eleq¹, Waleed I Albaker¹, Andrew
5 W. Brooks³, Ali I Al-Sultan¹, Abdullah M Al-Rubaish¹, Khaled R Alkharsah⁴, Raed M Sulaiman¹,
6 Abdulaziz A Al-Quorain¹, Cyril Cyrus⁵, Rudaynah A Alali¹, Chittibabu Vatte, Fred L. Robinson²,
7 Carrie Nguyen², Xin Zhou³, Michael P. Snyder³, Afnan F Almuhanha⁶, Brendan J Keating⁷, Brian
8 D. Piening², Ameen K Al-Ali⁵

9 1. Department of Internal Medicine, King Fahd Hospital of the University, Al-Khobar and
10 College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia

11 2. Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon,
12 USA

13 3. Department of Genetics, Stanford University School of Medicine, Stanford, California,
14 USA

15 4. Department of Microbiology, College of Medicine, Imam Abdulrahman bin Faisal
16 University, Dammam, Saudi Arabia

17 5. Department of Clinical Biochemistry, College of Medicine, Imam Abdulrahman bin Faisal
18 University, Dammam, Saudi Arabia

19 6. Department of Radiology, King Fahd Hospital of the University, Al-Khobar and College
20 of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia

21 7. Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA,
22 USA

23

24 **Running Title:** Saudi gut microbiota

25 *** Corresponding Author**

26 Email: aalali@iau.edu.sa (AKA)

27

28 These authors contributed equally to this work.

29

1 **Abstract**

2 Large-scale gut microbiome sequencing has revealed key links between microbiome
3 dysfunction and metabolic diseases such as T2D. To date, these efforts have largely focused on
4 Western populations, with few studies assessing T2D microbiota associations in Middle Eastern
5 communities where T2D prevalence is now over 20%. We analyzed the composition of stool 16S
6 rRNA from 461 T2D and 119 non-T2D participants from the Eastern Province of Saudi Arabia.
7 We quantified the abundance of microbial communities to examine any significant differences
8 between subpopulations of samples based on diabetes status and glucose level. We observed
9 overall positive enrichment within diabetics compared to healthy individuals and amongst diabetic
10 participants; those with high glucose levels exhibited slightly more positive enrichment compared
11 to those at lower risk of fasting hyperglycemia. In particular, the genus *Firmicutes* was upregulated
12 in diabetic participants compared to non-diabetic participants, and T2D was associated with an
13 elevated *Firmicutes/Bacteroidetes* ratio, consistent with previous findings. Based on diabetes
14 status and glucose levels of Saudi participants, relatively stable differences in stool composition
15 were perceived by differential abundance and alpha diversity measures.

17 **Author summary**

18 The rates of Type 2 diabetes (T2D) in Saudi Arabia have risen dramatically in the last
19 several decades due to socio-economic changes resulting in changes in dietary and sedentary
20 lifestyles. This emergence has grown more rapidly and affects larger proportions of the population
21 with estimates of T2D prevalence impacting 25% of the population. There is a paucity of
22 microbiome data from Middle Eastern populations, and previous studies have been conducted on

23 small sample sizes. Here we report on the first-ever characterization of gut microbiota T2D versus
24 non-T2D and largest microbiome study ever conducted in a Middle Eastern country. The datasets
25 from this study are important to create a regional reference T2D-microbiome catalogue which will
26 propel the understanding of regional gut flora which are associated with T2D development. Based
27 on T2D status and quantified glucose levels of Middle Eastern participants, relatively stable
28 differences in stool composition were observed by differential abundance and alpha diversity
29 measures. Comparing overlapping and varying patterns in gut microbiota with other studies is
30 critical to assessing novel treatment options in light of a rapidly growing T2D health epidemic.

31

32 **Introduction**

33 The human gut hosts 100 trillion microorganisms, encompassing thousands of species
34 collectively, weighing an average 1.5 kg per person [1,2]. The human microbiota is important
35 because of its metagenomic repertoire, which is estimated to be 100 times larger than the human
36 genome and encodes a vast array of functionality critical for host physiology and metabolism [2].
37 The bacterial components responsible for triggering these physiological functions are currently
38 the subject of intensive research. Differences in human gut microbiome composition have been
39 linked to metabolic diseases such as T2D and obesity [3-7]. Identifying specific bacterial
40 biomarkers within the microbiome could help predict the occurrence of T2D or tailor treatments
41 in high-risk subjects to prevent or delay the onset of metabolic diseases. The molecular
42 mechanisms through which the intestinal microbiota play a key role in metabolic diseases are
43 linked to an increased energy harvesting and the triggering of the low-grade inflammatory status
44 characterizing insulin resistance and obesity [8-9].

45 The prevalence of T2D is increasing worldwide, with current data indicating that at least
46 8.5% of the world's population is affected, with the worldwide prevalence expected to reach 12%
47 by 2025 [10-11]. T2D is mainly caused by insulin resistance and relative insulin deficiency [12].
48 Saudi Arabia, with a total population of over 20 million, has an estimated T2D constituting 25%
49 of the total population [13]. The rapid rate of increase of T2D disease in some areas of Saudi
50 Arabia, which increased from 16% in 2005 to over 25% in 2011, is thought to be due to rapid
51 lifestyle changes such as diet and sedentary lifestyle, as well as adverse environmental factors [13].

52 We analyzed the composition of 16S rRNA from the stool samples collected from Saudi
53 Arabian participants residing in the Eastern Province and quantified the abundance of microbial
54 communities to determine significant differences between subpopulations of samples based on
55 diabetes status and glucose level. We assessed alpha diversity between the subpopulations to
56 measure species richness and evenness among samples noting that an increased
57 *Firmicutes:Bacteroidetes* ratio has previously been observed in the microbiota of obese/diabetic
58 individuals compared to the microbiota of healthy individuals. Furthermore, individuals with
59 diabetes were tracked for high glucose level (>126 mg/dL) as it is an indicator of fasting
60 hyperglycemia, which could potentially lead to severe long-term complications including
61 cardiovascular disease, neuropathy and kidney failure.

62

63 **RESULTS**

64 Principal coordinate analysis (PCoA) of the generated 16S datasets is shown in Fig S2. The first
65 and second principal coordinates explained 25% and 7%; 29% and 7% and 34% and 6% of the
66 Diabetes Status and Gender variance, respectively. Levels of the 150 most abundant microbial

67 genera within T2D and non-T2D participants were observed to differ significantly in stool
68 microbiota abundance derived from 16S sequencing (Figures S3a and S3b).

69 Fig 1 (a and b) shows the rank abundant curve and Permutational Multivariate Analysis of
70 Variance (PERMANOVA) cloud, respectively for Saudi T2D and control 16S stool microbiota
71 datasets. These show that the microbiome communities differ globally between T2D and non-T2D
72 subjects at statistical significance, $p = 0.01$. The abundance of Taxonomic Composition in males
73 and females is clearly evident in both females (Figures S4a and S4b) and in males (Figures S5a
74 and S5b). We also compared Saudi T2D participants with higher glucose >126 mg/dL versus lower
75 glucose strata ≤ 126 mg/dL glucose using the top 150 genera. Amongst the 298 samples with
76 glucose data, $n=193$ were in the higher glucose strata and $n=105$ were in the lower strata (Figure
77 S6). Unlike previous studies conducted on Western populations, the Saudi participants with T2D
78 and higher glucose levels showed a trend toward increased diversity, a result that is similar to
79 another recently reported study from a United Arab Emirates (UAE) cohort [14].

80 **Figure 1: Rank abundant curve (a) and permutational multivariate analysis of variance**
81 **cloud (b) for Saudi T2D and control 16S stool microbiota datasets.** This figure shows the rank
82 abundant curve and Permutational Multivariate Analysis of Variance (PERMANOVA) cloud
83 respectively for Saudi T2D and control 16S stool microbiota datasets. These show that the
84 microbiome communities differ globally between T2D and non-T2D subjects at statistical
85 significance, $p = 0.01$.

86

87 Alpha diversity was compared in males versus females ($n = 204$ and 226 , respectively)
88 with no significant differences observed using various different classifications: ACE (Abundance-
89 based Coverage Estimator) and Chao1 indices to estimate richness (measurement of OTUs
90 expected in samples given all the bacterial species identified in the samples); Shannon-Weaver,
91 Simpson and Inverse Simpson to define different levels of resolution (phylum, class, order, family,

92 genus, and species); and Fisher (Fig S7). Alpha diversity of T2D versus non-T2D participants
93 revealed statistically significant enrichment of the Shannon-Weaver and Simpson metrics (Figure
94 S8) ($p < 2.26 \times 10^{-10}$ (CI: -0.392 to -0.718)) and $p < 4.63 \times 10^{-7}$ (CI: -0.049 to -0.108) for Shannon
95 and Simpson diversity, respectively. Saudi T2D cases versus controls showed an association with
96 an elevated *Bacteroidetes/Firmicutes* ratio, $p = 2.2 \times 10^{-5}$ t-test (Fig S9).

97 We observed an overall positive enrichment of microbiota genus/families for diabetics
98 compared to healthy individuals. In addition, among T2D patients, those with high glucose levels
99 exhibited slightly more positive enrichment compared to those at lower risk of fasting
100 hyperglycemia (Fig 2a and 2b and Table S1). In particular, the *Akkermansia*, *Acidaminococcus*,
101 *Megamonas*, *Dialister*, *Lactobacillus* and *Paraprevotella* genus were enriched at $p < 1 \times 10^{-9}$ in
102 T2D versus non-T2D. The *Fusobacterium*, *Dialister*, *Akkermansia* and *Prevotella* genus were
103 enriched in low versus high-risk T2D using a fasting glucose cutoff of 126 mg/dL.

104 **Figure 2: Fold Change plots of enriched OTUs for: T2D versus controls (a) and glucose levels**
105 **for high versus low T2D status (b).** An overall positive enrichment of microbiota genus/families
106 for diabetics compared to healthy individuals and amongst diabetic participants was observed.
107 Those with high glucose levels exhibited slightly more positive enrichment compared to those at
108 lower risk of fasting hyperglycemia.

109

110 Discussion

111 In this study we performed the largest microbiome study ever conducted in Saudi Arabia,
112 as well as the first-ever characterization of gut microbiota T2D versus non-T2D in this population.
113 We used shotgun metagenomic sequencing to obtain 16S rRNA reads identifiable down to genus
114 level from the stool samples of 461 T2D and 119 non-T2D Saudi participants from the Eastern
115 Province of Saudi Arabia, a region particularly affected by T2D [15]. We assessed the microbiota

116 abundance based on diabetes status and glucose levels, and examined community diversity patterns
117 to compare with other T2D microbiota studies from around the globe. These efforts are important
118 and warranted given the scarcity of microbiome data in Middle Eastern populations, and these
119 results provide a useful addition to the global microbiome reference dataset in an under-examined
120 community. Saudi Arabian T2D costs have risen over 500% in two decades with 10 million
121 individuals estimated to be diabetic or pre-diabetic, therefore comparing overlapping and varying
122 patterns in gut microbiota with other studies is critical to assessing novel treatment options in light
123 of a rapidly growing T2D health epidemic [15-16].

124 Community level differences are evident in the Saudi population between T2D and non-
125 T2D individuals, and diversity patterns appear to vary from well-characterized microbiota from
126 Western cohorts. Indeed, in contrast to Western cohorts that often show associations between
127 decreased gut microbiota diversity and insulin resistance, here we show that Saudi participants
128 with T2D exhibited higher relative diversity in comparison to normal metabolic counterparts [17].
129 These results are similar to a recent report from Al Bataineh and colleagues who characterized
130 microbiomes in a cohort of 50 T2D and non-T2D individuals from the United Arab Emirates,
131 though higher diversity in that smaller T2D cohort was determined to be insignificant when
132 controlling for age [14]. Sex was not found to play a role in community structural differences, and
133 results were independently validated between females and males. The role of overall community
134 diversity decreasing in T2D populations has been widely cited in early studies on Western
135 populations, yet larger meta-analyses involving global populations have distorted this pattern and
136 highlight the importance of locally representative studies [18].

137 We observe significant differences between T2D and non-T2D individuals for many
138 microbial taxa, as well as between T2D individuals with high and low fasting blood glucose levels.

139 Concordant with studies conducted on Western populations is the association of increasing
140 Bacteroidetes/Firmicutes ratio with T2D and in our overweight and obese T2D cohort, increased
141 Bacteroidetes may be functionally related to metabolism of branched chain amino acids which has
142 been linked to obesity-related metabolic phenotypes [3, 19]. Among OTUs assigned at the genus
143 taxonomic level, *Prevotella* and *Bacteroides* OTUs showed some of the most significant log-fold
144 increases in abundance for diabetics (over four-fold increases in abundance), species of which
145 have been functionally associated with the development of insulin resistance and glucose
146 intolerance [20]. Among Firmicutes however, levels of *Acidaminococcus* and *Megasphaera* were
147 positively correlated with T2D, as has been previously observed, and could functionally relate with
148 increases to Bacteroidetes through complementary amino acid metabolism [21-22]. We observed
149 higher levels of *Akkermansia* in the Saudi T2D group, despite potential protective effects for
150 obesity and metabolic disease. Associations of levels of *Akkermansia*, a mucus-consuming taxon,
151 have been observed to be associated with health and with ethnicity in Western populations and
152 may represent an impact of dietary and lifestyle effects on microbiota composition, as this microbe
153 is rarely observed in more traditional cultures across large geographic regions [23]. It should be
154 noted however that *Akkermansia* levels are also often increased in response to metformin intake
155 in T2D subjects (metformin use metadata is not known for the current cohort) [24]. Taxonomic
156 differences associated with T2D likely reflect shared or complementary functional and metabolic
157 traits but may be regionally specific based on dietary and environmental variations known to
158 influence the microbiome [23-25].

159 Based on diabetes status and quantified glucose levels of Middle Eastern participants,
160 relatively stable differences in stool composition were observed by differential abundance and
161 alpha diversity measures. Many studies have examined T2D associations with gut microbiota in

162 populations around the globe, and while some patterns generally validate across studies such as
163 individual taxon abundance variation, others such as overall community diversity do not replicate
164 consistently. Obesity, diet, lifestyle and ancestry are all factors that influence T2D and each varies
165 significantly from culture to culture around the globe, meaning that the patterns in T2D
166 development and roles of the microbiome likely vary as well. As a rapidly emerging chronic
167 condition in Saudi Arabia and the Middle East, T2D burdens have grown more quickly and affect
168 larger proportions of the population than any other global region, making a regional reference
169 T2D-microbiome dataset critical to understanding the nuances of disease development on a global
170 scale.

171

172 **Materials and Methods**

173 **Study Populations**

174 Between 2015-2019, stool samples and data were collected from 461 consecutive diabetic patients
175 attending the Diabetic Clinics, King Fahd Hospital of the University, Al-Khobar, Saudi Arabia
176 and from 119 healthy controls. Participants ranged in age from 30-75 years and had a body mass
177 index (BMI) ranging from 27 to 40 kg/m². The T2D patients had a minimum disease duration of
178 5 years. Table 1 outlines the patient demographics and clinical characteristics. Baseline
179 measurements included anthropometric measurements, physical examinations and in-person
180 surveys. Participants who had been treated with antibiotics in the previous three months, were
181 pregnant or lactating, or had inflammatory bowel disease were excluded from the study. Blood
182 and stool samples were collected from participants and were stored immediately after collection
183 at -80 °C. Ethical approval of the study was obtained from the local Institutional Review Board

184 (IRB) committee and the study was conducted according to the ethical principles of the Declaration
185 of Helsinki and Good Clinical Practice guidelines (IRB-2019-01-112). All participants provided
186 written informed consent.

187 **Table 1. Clinical and demographic characteristics for Saudi Arabian T2D cases (n=461) and**
188 **controls (n=119).**

	Ratio	Male	Female
Gender	1: 0.83	54.50%	45.50%
	Mean ± SD		
	Total	Male	Female
Age (Years)	52.6±8.83	51.82±9.28	53.5±8.25
Glucose(mg/dl)	165.7±68.89	161.45±57.71	166.8±74.09
HBA1c (%)	8.55±1.76	8.45±1.65	8.65±1.85
Duration (Years)	3-25	4-25	3-22
BMI (kg/m²)	27-40	27-37	30-40

189
190

191 **Methods for DNA library preparation and sequencing**

192 Sample collection and microbial DNA extraction were standardized to minimize confounding
193 effects of the technical procedure. Stool samples were taken from T2D (n=461) and from healthy
194 (n=119) participants. Fecal samples were provided by the patients whilst attending the outpatient
195 clinic and immediately stored at -20°C. The samples were subsequently transported on dry ice to
196 the research laboratory where they were stored at -80°C. Bacterial DNA extraction from stool
197 samples was performed using QIAamp Fast DNA Stool Mini Kit (Qiagen, Hilden, Germany)
198 according to the manufacturer's instructions. In brief, approximately 200 mg of stool was placed
199 in a 2 ml microcentrifuge tube and kept on ice. InhibitEX Buffer (1 ml) was added to each stool

200 sample, homogenized thoroughly by vortexing and incubated at 70°C for 5 minutes. Each sample
201 was centrifuged (20,000 g) for minute and 200 µl supernatant was pipetted into 1.5 ml
202 microcentrifuge tube containing 15 µl proteinase K and 200 µl lysis buffer and incubated at 70°C
203 for 10 minutes. This was followed by the addition of 200 µl of ethanol and mixed by vortexing.
204 The lysate (600 µl) was transferred to the QIAamp spin column and centrifuged (20,000 g) for 1
205 minute. Finally, the QIAamp spin column was opened and washed twice with two different
206 washing buffers. The DNA was eluted into a new 1.5 ml microcentrifuge tube by adding 200 µl
207 elution buffer. DNA samples were checked for purity using the Nanodrop 2000 Spectrophotometer
208 (ThermoFisher Scientific). Three independent extractions were performed from each sample to
209 ensure robust representation of all microbial content. DNA was stored at -80 °C till the time of
210 processing.

211 Sequencing was performed using either the Swift Amplicon 16S panel (Swift Biosciences)
212 or a custom protocol. For the Swift protocol, 20 ng of stool-derived DNA was used for 16S
213 sequencing library preparation using the 16S Primer Panel v2, the Swift Normalase Amplicon
214 Panels (SNAP) Core Kit, and the SNAP Combinatorial Dual Index Primer Kit (Sets 1A and 1B)
215 (Swift Biosciences, CA). The indexed libraries were on average 620 base pairs (bp) in length, and
216 individual DNA libraries were diluted to 2.5 nM, pooled in equimolar proportion, and sequenced
217 on a NovaSeq 6000 SP flow cell (Illumina, CA) using 250 bp paired-end reads. For the custom
218 approach, PCR was performed on each sample using the 515F primer (forward primer) and one of
219 the 100 806rcbc primers (reverse primer). These primers contained: sequence homologous to
220 region V4 of the 16S rRNA in forward and reverse; Illumina adaptors; and the reverse primers
221 contained indexing sequences. Taq PCR Master Mix from Qiagen was used to prepare the PCR
222 master mix. A PCR reaction was performed on each extracted DNA sample, i.e. each stool sample

223 had three PCR reactions. The PCR product was run on 1% agarose gel. The band of expected size
224 (381bp) was excised from gel and purified with gel purification kit from Qiagen. The three PCR
225 products from each sample were pooled together. The pooled and purified PCR product was
226 quantified with NanoDrop 2000 (Thermo Sciences, USA).

227 Equal concentrations of DNA from each sample (5ng of DNA) were pooled together. For
228 each sequencing run, DNA from 50 samples was pooled to make the DNA library for each batch.
229 The final concentration of the DNA library was quantified with real time PCR using the Kapa
230 library quantification kit (Roche, USA) according to the manufacturer's instructions. The DNA
231 library of each batch was sequenced using the MiSeq platform from Illumina (Illumina, USA)
232 using the MiSeq reagent V2 500cycles Kit from Illumina and the custom read1
233 (TATGGTAATTGTGTGCCAGCMGCCGCGGTAA), read2 (AGTCAGTCAGCCGGACTACH
234 VGGGTWTCTAAT) and index (ATTAGAWACCCBDGTAGTCCGGCTGACTGACT)
235 sequencing primers. PhiX DNA (Illumina, USA) was used as a control library.

236

237 **Analyses**

238 Figure S1 overviews the analytical pipeline and workflow employed for these analyses. 16S rRNA
239 (V4 region) sequences were used in this study and sequenced with Illumina software which
240 handled the initial primer and barcode processing of all raw sequences. Raw sequences were
241 demultiplexed with Illumina's bcl2fastq2 v2.20 [26]. FastQC was then used for further processing
242 to remove samples with low quality scores across the majority of bases [27]. After de-multiplexing
243 the raw sequences and screening via FastQC, the majority of data processing was executed in
244 QIIME2 with custom scripts. Paired-end reads were joined using VSEARCH. Chimera amplicon
245 removal and abundance filtering were processed using Deblur [28]. Amplicon sequences were

246 clustered and assembled into Operational Taxonomical Units (OTUs) using closed reference
247 clustering against the Greengenes 13_8 database via VESEARCH. Taxonomic assignment was
248 performed using a pre-trained Naïve Bayes classifier with Greengenes OTU database. The
249 abundance tables and data obtained from QIIME2 were combined into a Phyloseq object and
250 further analyzed in R with custom scripts [29].

251

252 **Acknowledgement**

253 The authors would like to acknowledge the financial supported extended by King Abdulaziz City
254 for Science and Technology, Riyadh, Saudi Arabia, grant numbers 12-MED2799-46 and 13-
255 MED1881-46. We are also grateful to the nurses and technical staff for their work and dedication.

256 **References**

- 257 1. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut
258 microbial gene catalogue established by metagenomic sequencing. *Nature*.
259 2010;464(7285):59-65.
- 260 2. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human
261 microbiome project. *Nature*. 2007;449(7164):804-10.
- 262 3. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et
263 al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults.
264 *PLoS One*. 2010;5(2):e9085.
- 265 4. Greenhill C. Obesity: Gut microbiota, host genetics and diet interact to affect the risk of
266 developing obesity and the metabolic syndrome. *Nat Rev Endocrinol*. 2015;11(11):630.
- 267 5. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
268 Reproducible, interactive, scalable and extensible microbiome data science using QIIME
269 2. *Nat Biotechnol*. 2019;37(8):852-7.
- 270 6. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al.
271 *Akkermansia muciniphila* and improved metabolic health during a dietary intervention in
272 obesity: relationship with gut microbiome richness and ecology. *Gut*. 2016;65(3):426-36.
- 273 7. Piening BD, Zhou W, Contrepois K, Röst H, Gu Urban GJ, Mishra T, et al. Integrative
274 Personal Omics Profiles during Periods of Weight Gain and Loss. *Cell Syst*.
275 2018;6(2):157-70.e8.
- 276 8. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest*.
277 2006;116(7):1793-801.

- 278 9. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444(7121):860-7.
- 279 10. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes
280 mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative
281 meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215-22.
- 282 11. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic.
283 *Nature*. 2001;414(6865):782-7.
- 284 12. Association AD. 2. Classification and Diagnosis of Diabetes. *Diabetes Care*.
285 2017;40(Suppl 1):S11-S24.
- 286 13. Alotaibi A, Perry L, Gholizadeh L, Al-Ganmi A. Incidence and prevalence rates of
287 diabetes mellitus in Saudi Arabia: An overview. *J Epidemiol Glob Health*. 2017;7(4):211-
288 8.
- 289 14. Al Bataineh MT, Dash NR, Bel Lassen P, Banimfreg BH, Nada AM, Belda E, et al.
290 Revealing links between gut microbiome and its fungal community in Type 2 Diabetes
291 Mellitus among Emirati subjects: A pilot study. *Sci Rep*. 2020;10(1):9624.
- 292 15. Alshayban D, Joseph R. Health-related quality of life among patients with type 2 diabetes
293 mellitus in Eastern Province, Saudi Arabia: A cross-sectional study. *PLoS One*.
294 2020;15(1):e0227573.
- 295 16. Robert AA, Al Dawish MA, Braham R, Musallam MA, Al Hayek AA, Al Kahtany NH.
296 Type 2 Diabetes Mellitus in Saudi Arabia: Major Challenges and Possible Solutions. *Curr*
297 *Diabetes Rev*. 2017;13(1):59-64.
- 298 17. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human
299 gut microbiome correlates with metabolic markers. *Nature*. 2013;500(7464): 541-6.

- 300 18. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota
301 in type 2 diabetes pathophysiology. *EBioMedicine*. 2020;51:102590.
- 302 19. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from
303 twins discordant for obesity modulate metabolism in mice. *Science*.
304 2013;341(6150):1241214.
- 305 20. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et
306 al. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature*.
307 2016;535(7612):376-81.
- 308 21. Gaike AH, Paul D, Bhute S, Dhotre DP, Pande P, Upadhyaya S, et al. The Gut Microbial
309 Diversity of Newly Diagnosed Diabetics but Not of Prediabetics Is Significantly Different
310 from That of Healthy Nondiabetics. *mSystems*. 2020;5(2).
- 311 22. Yang Q, Lin SL, Kwok MK, Leung GM, Schooling CM. The Roles of 27 Genera of Human
312 Gut Microbiota in Ischemic Heart Disease, Type 2 Diabetes Mellitus, and Their Risk
313 Factors: A Mendelian Randomization Study. *Am J Epidemiol*. 2018;187(9):1916-22.
- 314 23. Smits SA, Leach J, Sonnenburg ED, Gonzalez CG, Lichtman JS, Reid G, et al. Seasonal
315 cycling in the gut microbiome of the Hadza hunter-gatherers of Tanzania. *Science*.
316 2017;357(6353):802-6.
- 317 24. de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona
318 JA, Abad JM, et al. Metformin Is Associated with Higher Relative Abundance of Mucin-
319 Degrading *Akkermansia muciniphila* and Several Short-Chain Fatty Acid-Producing
320 Microbiota in the Gut. *Diabetes Care*. 2017;40(1):54-62.

- 321 25. Yatsunenکو T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al.
322 Human gut microbiome viewed across age and geography. *Nature*. 2012;486(7402):222-
323 7.
- 324 26. H. Li, Seqtk: a fast and light weight tool for processing FASTA or FASTQ sequences,
325 2013. <https://github.com/lh3/seqtk>
- 326 27. Andrews, S. (2010). FastQC: A Quality Control Tool for High Throughput Sequence Data
327 [Online]. Available online at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>
- 328 28. Amir A, McDonald D, Navas-Molina JA, Kopylova E, Morton JT, Zech Xu Z, et al. Deblur
329 Rapidly Resolves Single-Nucleotide Community Sequence Patterns. *mSystems*.
330 2017;2(2).
- 331 29. McMurdie, P.J. & Holmes, S. Phyloseq: An R Package for Reproducible Interactive
332 Analysis and Graphics of Microbiome Census Data. *PLoS One*8, (2013).

333

334 **Supporting information**

335 **Fig S1:** Data processing and analyses pipeline for Saudi T2D 16S microbiota study.

336 **Fig S2:** Principal coordinate analyses of 16S microbiota data from Saudi T2D and control
337 participants using: (a) sex and (b) T2D status.

338 **Fig S3a:** Heatmap of top 150 genus for (a) non-T2D and (b) T2D (OTU abundance based on
339 BrayCurtis dissimilarity).

340 **Fig S3b:** Heatmap of top 50 genus for (a) non-T2D and (b) T2D individuals listed, respectively.

341 **Fig S4a:** Heatmap of top 150 gut microbiota 16S genus for (a) T2D and (b) T2D in Saudi females
342 (OTU abundance based on BrayCurtis dissimilarity).

343 **Fig S4b:** Abundance of gut microbiota 16s taxonomic composition of: a) non-T2D vs (b) T2D in
344 Saudi females

345 **Fig S5a:** Heatmap of top 150 gut microbiota 16S genus: (a) non-T2D (b) T2D in Saudi males
346 (OTU abundance based on BrayCurtis dissimilarity).

347 **Fig S5b:** Abundance of gut microbiota 16S taxonomic composition of: (a) non-T2D versus (b)
348 T2D in Saudi males.

349 **Fig S6:** Heatmap of top 150 genus for Saudi 16S gut microbiota for individuals with: (a) < 126
350 mg/dL and (b) >126 mg/dL (OTU abundance based on BrayCurtis dissimilarity).

351 **Fig S7:** Alpha diversity 16S gut microbiota assessment in Saudi males and females using: Chao1,
352 ACE, Shannon-Weaver, Simpson, Inverse Simpson and Fisher indices.

353 **Fig S8:** Shannon and Simpson Alpha diversity: (a) T2D versus (b) non-T2D status.

354 **Fig S9:** *Bacteroidetes-Firmicutes* ratio in Saudi non-T2D cases and controls using 16S gut
355 microbiota data.

356 **Table S1:** The most divergent microbiota genus between Saudi T2D cases and controls (a) and
357 between T2D cases with high (> 126 mg/ dL) and low (< 126 mg/ dL) glucose (b). Positive 16S
358 fold change indicates upregulation in diabetics.

Fig 1: Rank abundant curve (a) and permutational multivariate analysis of variance (PERMANOVA) cloud (b) for Saudi T2Ds and Control 16S stool microbiota datasets. This figure shows the rank abundant curve and Permutational Multivariate Analysis of Variance (PERMANOVA) cloud respectively for Saudi T2D and control 16S stool microbiota datasets. These show that the microbiome communities differ globally between T2D and non-T2D subjects at statistical significance, $p = 0.01$.

bioRxiv preprint doi: <https://doi.org/10.1101/2021.10.25.465666>; this version posted October 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 1a

b




Figure 1b

Fig 2: Fold change plots of enriched OTUs for: T2D vs controls (a) and glucose levels for high vs low T2D status (b). An overall positive enrichment of microbiota genus/families for diabetics compared to healthy individuals and amongst diabetic participants was observed. Those with high glucose levels exhibited slightly more positive enrichment compared to those at lower risk of fasting hyperglycemia.




Figure 2a

